All Industries

Minerva Surgical Launches Next Generation Symphion Fluid Management Accessory with Fluid Deficit Readout

Minerva Surgical, Inc.

Minerva Surgical, a manufacturer and distributor of minimally invasive gynecologic surgical technologies, today announced the launch of the Symphion Fluid Deficit Readout, an optional accessory that provides fluid deficit volume readings during operative hysteroscopy procedures. Operative hysteroscopy is a surgical procedure that requires precise fluid management to prevent complications. The Symphion Fluid Deficit Readout, which is intended for use with the Symphion Operative Hysteroscopy System, automatically calculates the fluid deficit during the procedure by measuring the weight of the saline bag throughout the procedure in real time and converting the weight measurement into fluid volume readings. Additional key features of the Symphion Fluid Deficit Readout include a fluid deficit accuracy within +/- 50mL, a user-friendly interface with an intuitive display for easy operation, and a compact design that allows for quick set up with the Symphion controller. “Continuous innovation with a focus on enhancing patient safety has always been the primary objective for Minerva Surgical. The Symphion Operative Hysteroscopy System is intended to volumetrically limit a patient’s exposure to fluid so the risk of fluid absorption and overload can be avoided. With the introduction of the Symphion Fluid Deficit Readout, the system has a new layer of procedural safety to complement the unprecedented precision during uterine cavity tissue resection.”, states Minerva Surgical Chief Medical Officer Eugene Skalnyi, M.D. Along with the Symphion Fluid Deficit Readout, Minerva Surgical is launching a compatible, next generation of Fluid Management Accessory called INFINITY. Together, the Symphion line extensions are the newest additions to the Minerva Surgical portfolio of minimally invasive technologies. The company is committed to advancing gynecologic surgery and providing solutions that enhance outcomes. About Minerva Surgical, Inc. Minerva Surgical is a technology enabled medical device company focused on developing, manufacturing, distributing, and commercializing minimally invasive solutions to meet the distinct pelvic healthcare needs of women. The Company has established a broad product line of minimally invasive alternatives to hysterectomy, which include solutions to detect and address common causes of Abnormal Uterine Bleeding (AUB). The Minerva Surgical pelvic health solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the anatomy by avoiding unnecessary hysterectomies. For more information about the innovative medical devices of Minerva Surgical, please visit www.MinervaSurgical.com. Contact Details Kevin Tracey +1 855-646-7874 kevin.tracey@minervasurgical.com Company Website https://minervasurgical.com/

August 26, 2024 10:00 AM Eastern Daylight Time

AmeriLife’s Senior Market Advisors Welcomes Parker Marketing Insurance to Expand Presence in the Medicare Advantage and Final Expense Markets

AmeriLife

Senior Market Advisors (SMA), a fast-growing field marketing organization (FMO) in the insurance space and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has completed its acquisition of Parker Marketing Insurance (“PMI”). Per the agreement, terms of the deal were not disclosed. “Daniel [Parker] and his team represent the kind of customer-focused care that we promote in every interaction our affiliated agents and agencies have with their clients,” said Joshua Borders, CEO of Senior Market Advisors. “This partnership represents our shared values in meeting people where they are in their health insurance journey and helping them safeguard their assets for some of life’s unexpected events.” Inspired by his experiences and what he learned from his father, Parker established his first insurance agency in 2016, focused on replicating a successful final expense business into the Medicare Advantage market. This pivotal decision led to PMI’s Legacy Chassis—a primary brokerage model that benefits agents through a tiered lump sum model, enhancing recruitment efforts. “AmeriLife’s distribution platform offers robust layers of professionalism to ensure success for PMI’s agents and customers,” said Daniel Parker, owner and president of Parker Marketing Insurance. “This partnership will fuel my long-term vision, allowing me to continue my life’s work for the people I serve, enabling continued growth, and enhancing agent success emphasized by the power and unity of AmeriLife’s core values that prioritize the needs and success of others.” PMI’s growing, nationwide agent network—specifically, across the southeast in Mississippi, Georgia, and Florida—is a testament to its focus and dedication to talent acquisition and best-in-class training protocols, which have developed some of the region’s top producers. AmeriLife provides partners with a business environment and distribution network characterized by efficiency, value, and access to teams of dedicated professionals working together to enhance their platform with productivity and profitability. This proves especially advantageous for companies like PMI focused on the Medicare and final expense sectors, where consumers search for peace of mind and customized solutions to address their healthcare needs and end-of-life expenses. "Seeing our collaboration with Senior Market Advisors flourish through the years, and now with the inclusion of Parker Marketing Insurance, is exciting," added Scotty Elliott, Chief Distribution Officer of Health for AmeriLife. "This expansion highlights the robust nature of our expanding Health Distribution network, enabling us to assist more beneficiaries and establish new benchmarks in top-tier customer service within the industry." ### About Parker Marketing Insurance Parker Marketing Insurance helps people navigate the complex world of insurance, focusing on Medicare Advantage, Medicare Supplement, Medicare Part D, Dental & Vision Insurance, Hospital Indemnity, and Final Expense. Based in Meridian, MS, Parker Marketing Insurance is staffed by proven insurance professionals committed to providing consumers with highly personalized service. For more information, visit www.pmiagents.com. About Senior Market Advisors Senior Market Advisors (SMA) has been people over profits since 2007, by hard work and a commitment to “doing right” by the consumer. We have certainly knocked on our fair share of doors. We know the grit and determination involved in becoming a career agent. As a result, we are a fast-growing FMO, doubling our business each year for the past five years. For more information, visit us online at www.SeniorMarketAdvisors.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a distribution network of over 300,000 insurance agents, financial professionals, and over 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn. Contact Details AmeriLife Jeff Maldonado media@amerilife.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

August 26, 2024 09:00 AM Eastern Daylight Time

Linqto’s Plan To Bring More Wealth Generation Opportunities To A Generation Of Investors That’s Wary Of Traditional Financial Institutions

Benzinga

By Kyle Anthony, Benzinga A recent Wall Street Journal highlighted that Millennials, in general, don’t trust traditional financial institutions. The disappointment that individuals within the Millennial and Generation Z demographic have towards traditional financial institutions is partly borne from their lived experience, as over the past two decades, they have lived through the Financial Crisis of 2007-2008, read congressional hearing transcripts about Citadel Securities' involvement in the Robinhood (NASDAQ: HOOD) “Meme Stock” controversy and seen the failure of three banks, namely, Signature Bank, Silicon Valley Bank and First Republic Bank, which stoked fear in equity markets and initiated a run on the bank in certain regions. Despite the adverse nature of the previously mentioned events, young people remain optimistic about their financial future, with 58% of Gen Z and 49% of Millennials expecting their financial situation to improve this year, according to a Bankrate survey. However, one concern among many is the built-in exclusivity and inaccessibility of many lucrative financial investments, and many young people are eschewing traditional asset classes, opting to use alternative investments to build their wealth. Against this backdrop, Linqto, a San Jose, California-based firm, wants to reshape the financial landscape by providing individuals access to private investments before they become publicly traded. Providing Wealth-Generating Opportunities For Young Investors A recent article by the World Economic Forum found that young people are actively investing. The World Economic Forum’s Global Retail Investor Survey found that 70% of retail investors are under the age of 45. With Millennials and Generation Z having lived through the ‘venture capital era’ and witnessed the entrepreneurial rise of Facebook, now called Meta Platforms (NASDAQ: META), Uber (NYSE: UBER) and Airbnb (NASDAQ: ABNB) – companies that grew from innovative upstarts to industry leaders – many young people have an appreciation and understanding as to how being an early, pre-IPO investor in private companies can lead to generational wealth. Given the wealth generation that can be attained through private market investments, Linqto's mission is to make investing in private companies as easy and accessible as investing in the public stock market. The platform features high-growth, technology-driven companies that they believe will go public or be acquired within five years. Accessing Private Markets With Linqto Linqto's approach to private market investing is distinct from its peers. First, the company primarily invests in mid-to-late-stage private companies within the technology industry. Selected firms must generate a minimum revenue amount with institutional venture capital or private equity investor backing. Linqto seeks to invest in visionary leaders and management teams with a proven track record of bringing timely products and services to market. The platform's investment thematic focus generally falls within the technology sub-verticals of artificial intelligence, blockchain and digital assets, enterprise software, networking and IoT, hardware and FinTech. Secondly, Linqto conducts in-depth due diligence on the firms it includes on its platform as it invests alongside its investors. By investing first and ensuring that Linqto has skin in the game, the firm can streamline the investment process, making it as easy as pointing and clicking to participate in the investment opportunities presented on the platform. Leveraging its in-house research expertise and evaluation capabilities, Linqto says it can offer access to top private companies with industry-low minimums and no fees. To learn more about Linqto’s investment offerings, click here. Finally, Linqto says its fee structure is also a key differentiator, as it is a zero-fee investment management platform. Given that the company purchases shares in large quantities from founders, employees and investors, it receives shares at a negotiated price. Linqto can then make smaller quantities of its shareholdings available to investors at a reasonable markup, thus eliminating the need for further follow-on fees for the investor. Historically, investing in a private company required individuals to invest at least $100,000. Linqto's initial minimum investment amount is $2,500, with subsequent investment amounts being $5,000. In comparison to the pricing structure of other private investment platforms, such as Forge Global Holdings (NYSE: FRGE), EquityZen and HIIVE, Linqto’s fee structure is very advantageous to retail investors desiring access to private investment opportunities. Furthermore, the self-directed investment platforms of Charles Schwab Corp. (NYSE: SCHW) and Robinhood (NASDAQ: HOOD) primarily cater to public equity investments, not private markets. Linqto: A New Avenue For Wealth Generation Linqto plans to revolutionize the investment journey in the private market by making it affordable, accessible and easy. With many companies remaining private for longer, Linqto’s platform is a new avenue through which young investors can gain early, pre-IPO access to companies that could potentially be poised to be industry leaders. As demand for private investments grows, Linqto’s platform can help investors looking to broaden their investment opportunities in a turnkey manner. To learn more and begin investing with Linqto, click here! Featured photo by Joshua Mayo on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 26, 2024 09:00 AM Eastern Daylight Time

Image

Wolfpack Financial Has A Plan To Help Millennials And Gen Z Attain Their American Dream

Benzinga

By Anthony Termini, Benzinga Many Americans aged 18 to 27 either still live with their parents or rely on them for some financial support, according to a recent survey conducted by Bank of America. Tax and accounting consultants, Ernst & Young point out in a similar survey that more than half of GenZers say they are worried about not having enough money. In 2021 an article on the HuffPost website, explained how "millennials are facing the scariest financial future of any generation since the Great Depression." Prior to that, The Wall Street Journal conducted a survey that found "more than half of millennials surveyed feel overwhelmed by financial obligations." Their survey also noted that they don’t trust traditional financial institutions. Layered atop these sentiments is the reality that the way Americans earn a living is changing. According to management consultants McKinsey & Company, in 2022, some 58 million Americans identified themselves as independent (or gig) workers. TechReport.com notes that “over two-thirds of full-time gig workers find it a more secure form of employment than a regular job.” All of this seems to support what think tank New America, has reported. They found that in general, "Americans believe the American Dream… is becoming more difficult to attain." Amid such a landscape, one company may offer Millennials and Gen Zers a reason to feel optimistic about their financial futures. Wolfpack Financial Is Poised To Roll Out A Novel Approach To Investing Wolfpack Financial is a native app investment company focused on helping Millennials and Gen Zers control their finances and build generational wealth. The company, incorporated in Delaware with headquarters in New York, is not a traditional brokerage. Wolfpack offers an investment opportunity with multiple benefits for beginning and inexperienced investors. For example, the app makes it possible for an investor to open an account with a minimum of $5. What’s more, Wolfpack offers up to $50 in rewards to new customers meeting certain conditions who download the mobile app and fund their accounts with a minimum of $100. These same customers also automatically receive pre-approval for up to $2,000 in “Booster Loans” and priority access to them when they are launched later this year. Wolfpack’s Booster Loan program is one of the features that makes the app unique and particularly beneficial for the young customer base the company caters to. Booster Loans are a type of lending product that gives investors an opportunity to augment their cash purchases. The patent-pending innovation is a Buy-Now-Pay-Later system for buying stocks and ETFs. Wolfpack’s technology allows a customer to use smart leverage to purchase assets and then pay back the borrowed funds over a fixed 10-week repayment schedule. Booster Loans make it possible for an investor with $100 cash to invest up to $200 in a stock or ETF. Individual Wolfpack customers enjoy this unique investment opportunity, and the company also has an enterprise version it intends to license to banks and brokerage firms that don’t have a similar offering or functionality. Wolfpack notes that more than 90% of such U.S. institutions fall into that category, which results in cash outflows to other companies that do provide those services. Booster Loans are the only fully collateralized Buy-Now-Pay-Later lending product on the market, says Wolfpack, and the company will use it to help its strategic partners be more competitive with firms like Robinhood Markets (NASDAQ: HOOD) or WeBull. Another factor that makes Wolfpack unique in the industry is that there are no penalties for consumers using the Wolfpack app. The company also offers commission-free trades and fractional share trading and lets investors buy securities for as little as $5.00 per trade. Wolfpack prides itself on its product, noting that Booster Loans are a better alternative to personal loans, credit cards and traditional margin lending because of its lower interest rate. Why Millennials And Gen Zers May Want To Begin Their Investment Journeys Now While the financial stress felt by Millennials and Gen Zers is real, there is still much for them to be optimistic about. Collectively, they stand to benefit from one of the greatest wealth transfers in history. Some $84 trillion is expected to be inherited by these Americans in the next 20 years – about $16 trillion of that will be transferred in the next decade. Wolfpack believes that an important part of being able to manage that future wealth can be gained from the investment experience and education it offers to the current generation of beginning and inexperienced investors. These may be some of the greatest benefits Wolfpack users get from the app. Investment information about Wolfpack is available on the Wefunder website, and those interested in the Rewards and Priority Access being offered to new account holders should visit the company’s website. Featured photo by Nattanan Kanchanaprat from Pixabay. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 26, 2024 08:50 AM Eastern Daylight Time

Image

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Benzinga

By Kyle Anthony, Benzinga The growing prevalence of cancer is not limited to adults; it is also afflicting children. An estimated 15,780 children between birth and 19 years of age are diagnosed with cancer each year in the U.S., according to the American Childhood Cancer Organization. Approximately 1 in 285 children in the U.S. will be diagnosed with cancer before their 20th birthday. Globally, there are more than 300,000 children diagnosed with cancer each year, and the rate of childhood cancer is slowly rising; cancer cases increased to 177 per million in 2019 from 165 per million in 2003. Recently, Theriva Biologics (AMEX: TOVX), the clinical-stage immuno-oncology company developing therapies for difficult-to-treat cancers, was granted Rare Pediatric Drug Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of retinoblastoma; the most common type of eye cancer in children. Retinoblastoma Presents Significant Treatment Challenges Retinoblastoma is a tumor that originates in the retina and accounts for approximately 2% of all childhood cancers. Some 200 to 300 children are diagnosed each year in the U.S., and the cancer is most common among infants and young children. The average age of a child when diagnosed is two years of age. Approximately three out of four children with retinoblastoma have a tumor in only one eye (known as unilateral retinoblastoma). When both eyes are affected it is known as bilateral retinoblastoma. Although the chances of developing retinoblastoma are statistically low, the challenge of preserving life while preventing the loss of an eye, blindness, and other severe consequences that diminish both lifespan and quality of life remains significant. Furthermore, in low-resource countries, children with retinoblastoma face a higher risk of losing their eyes and succumbing to metastatic disease. Recently, market research and industry consulting firm Spherical Insights assessed the global retinoblastoma treatment market size to be $2.5 billion in 2023; and it is expected to grow to $3.8 billion by 2033. Rare Pediatric Drug Designation For VCN-01 As the name suggests, the Rare Pediatric Drug Designation is a special status given to drugs explicitly developed for treating rare diseases that affect children. This designation is part of a broader effort to encourage the development of medications for conditions not commonly addressed due to the small number of patients, particularly in the pediatric population. For Theriva Biologics, this designation comes with a key incentive: if a Biologics License Application for VCN-01 for the treatment of retinoblastoma is approved by the FDA, Theriva says it may be eligible to receive a Priority Review Voucher (PRV) that can be redeemed to receive a priority review for any subsequent marketing application or may be transferred or sold. PRVs have previously been sold by different companies for around $100M. “The FDA’s decision to grant rare pediatric drug designation to VCN-01 highlights the urgent need for new treatment options for pediatric patients with retinoblastoma. We are encouraged by this important step forward and, in parallel, continue to work closely with leading physicians and regulatory agencies to refine our clinical strategy for VCN-01 as an adjunct to chemotherapy in pediatric patients with advanced retinoblastoma,” said Steven A. Shallcross, CEO of Theriva Biologics. “Most recently, results from the investigator-sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma were determined to be positive by the study Monitoring Committee. Data from this study will further inform our clinical development pathway in this area of high unmet need,” he said. With VCN-01 receiving RPDD from the U.S. FDA, this milestone speaks to the drug's efficacy and long-run potential. As such, the social benefit that Theriva Biologics provides could continue to grow and have increased industry resonance. Featured photo by Ani Kolleshi on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 26, 2024 08:45 AM Eastern Daylight Time

Image

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack’s Plans To Transform The Continuous Glucose Monitoring Market

Benzinga

By Meg Flippin, Benzinga Managing diabetes has gotten an overhaul thanks to continuous glucose monitoring devices (CGM). Glucotrack Inc. (NASDAQ: GCTK), the Rutherford, New Jersey medical technology company that makes a continuous blood glucose monitoring (CBGM) device, is seeking to position itself to transform the glucose monitoring market. It is doing so through what it says is a game-changing medical technology that overcomes the challenges of the existing devices on the market, including the lack of real-time accuracy, the need for frequent sensor changes and concerns regarding comfort and wearability. Glucotrack’s implantable Continuous Blood Glucose Monitor (CBGM) measures glucose in the blood, something no other known competitor is offering to date. By measuring glucose in the blood instead of glucose in interstitial fluids – which is what most other devices measure – users get an accurate, real-time reading. Plus, Glucotrack’s implant can last up to three years, compared to less than one year for many of the continuous glucose monitoring (CGM) devices on the market. Patients don’t have to worry about sticking an adhesive to their body or be concerned about it falling off during physical activity, whether it's swimming or hot yoga. The CBGM, which also requires minimal calibration, eliminates the hassle and discomfort of a wearable that requires frequent replacement, the company said. Making The Rounds Glucotrack has been busy getting the word out about the potential of its CBGM. In June, it presented two posters at the American Diabetes Association (ADA) 84th Scientific Sessions discussing preclinical animal studies and a sensor longevity simulation modeling for its CBGM. The ADA Scientific Sessions is one of the premier diabetes conferences which provides a platform for the latest advancements in diabetes research, prevention and care. This annual meeting provides researchers and healthcare professionals with the opportunity to share ideas and learn about cutting-edge technologies and breakthroughs in diabetes research and diabetes-related conditions. Glucotrack also presented an emerging science industry poster at the Association of Diabetes Care and Education Specialists annual conference, which took place from Aug. 9 to 12. The poster presented market research data on the acceptance of the company’s CBGM concept among people with type 1 and type 2 diabetes. It highlighted that out of 757 respondents with type 1 and type 2 diabetes using a variety of insulin regimens, there was a positive sentiment towards the CBGM concept, with over 50% of potential users open to adopting the product. In other words, the CBGM concept could be a viable alternative to existing products on the market. PreClinical Trials In The Bag Glucotrack’s data so far seems to back up its claims, including its recent 90-day preclinical study demonstrating the sustained accuracy of its CBGM. The second long-term preclinical study for its CBGM showed a Mean Absolute Relative Difference (MARD) of 4.7% at day 90, which is considered highly accurate for a continuous glucose monitor, reports Glucotrack. MARD is a key metric used to assess the accuracy of glucose monitoring devices, measuring the average difference between the CBGM device’s measurement and a reference measurement, most often obtained via capillary blood glucose. Lower values indicate better performance, said Glucotrack. The company said the 90-day preclinical study, which included a larger number of animal subjects and a longer duration than the initial 60-day study announced earlier this year, further validates the CBGM’s sustained accuracy and performance. “We are again very pleased with the performance of our sensor during a long-term preclinical study and look forward to moving into human clinical trials,” stated Paul Goode, PhD, president and CEO of Glucotrack. “Our CBGM’s ability to continuously measure blood glucose for 3 years with accuracy, minimal calibration and without a wearable device represents a significant advancement in glucose monitoring. We believe this technology has the potential to greatly improve the quality of life for people with diabetes by providing a more convenient and discreet monitoring solution,” he said. Cashing In All of these developments seem to have brought Glucotrack investment money; in July, the company secured $4 million in funding from its leading shareholder to support its upcoming first in-human clinical trial. It also helps the company that it has a deep leadership bench and board with years of experience. Take Goode, for starters. He has decades of experience developing innovative medical technologies in the implantables and glucose monitoring space for big-name medical technology companies, including DexCom Inc. (NASDAQ: DXCM), a global continuous glucose monitoring company. Goode is a named inventor on over 150 issued patents, including over 100 relating to Dexcom’s continuous glucose sensing technology. Meanwhile, Mark Tapsak, Ph.D., VP of Sensor Technology, has held senior positions at diabetes management companies, including as senior scientist at DexCom. Further, the bench just got deeper with the appointment of Andy Balo – a former DexCom executive – to the board. Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002, he joined DexCom as part of the original executive team where he remained for the next 22 years, playing a key role in shaping the company’s future. During his tenure, he was responsible for numerous glucose monitoring regulatory submissions and clinical trials worldwide, and coordinated quality activities across multiple manufacturing facilities. With a forecasted CAGR of 10.3% over 2024-2034, the continuous glucose monitoring market could be poised to take off, and Glucotrack wants to play a role in expanding options for patients with its technology. With preclinical trials already being in the bag, and human trials up next - the company feels its commitment to that goal is progressing steadily toward fruition. Featured photo by Mykenzie Johnson on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 26, 2024 08:30 AM Eastern Daylight Time

Image

News Release

Core X Solutions, Headed by Hani Saleh, Introduces Innovative Gift Card and Voucher Service

Rev Up Marketers

Core X Solutions is proud to introduce a groundbreaking new service under the leadership of Hani Saleh, CEO and Co-Founder. This innovative platform is set to transform the way consumers and businesses acquire and resell gift cards and vouchers, offering unprecedented convenience, value, and integration capabilities. The new service leverages Core X’s advanced technology to aggregate gift cards and vouchers from multiple reliable sources. This ensures a wide range of options, allowing users to find exactly what they need at the most competitive prices available. Whether you're a consumer looking for a specific gift card or a business aiming to resell vouchers, Core X’s platform guarantees the best deals on the market. Core X Solutions stands out with its best price guarantee. By sourcing from various providers, the platform ensures that both individual consumers and businesses receive the lowest possible prices. This applies equally to end-users purchasing for personal use and businesses integrating the service via API for resale purposes. The service is particularly beneficial for businesses, offering a powerful API that facilitates seamless integration into their existing systems. This feature empowers businesses to easily resell gift cards and vouchers, thus opening up new revenue streams. The API is designed for efficiency, helping businesses reduce operational costs while enhancing their service offerings. Hani Saleh, the visionary behind Core X Solutions, commented on the launch: “Our new gift card and voucher service is a testament to our commitment to innovation and delivering exceptional value to our customers. By aggregating multiple sources and ensuring the best prices, we are simplifying the process for consumers and empowering businesses to thrive. This launch marks a significant step forward in our mission to enhance user experience and support business growth.” The launch of this service comes at a crucial time when both consumers and businesses are looking for more efficient and cost-effective ways to manage gift card and voucher transactions. By combining a user-friendly interface with powerful backend integration, Core X Solutions is positioned to become a leader in this space, providing a service that is not only reliable but also adds tangible value to its users. About Core X Solutions: Core X Solutions continues to lead the industry in providing innovative self-service and business optimization solutions. With a focus on quality, innovation, and customer satisfaction, the company is committed to driving growth and efficiency for businesses worldwide. For more information about the new gift card and voucher service, and to explore how it can benefit you or your business, visit Core X Solutions. Contact Details Core X Solutions Mr. Hani Saleh info@corex.solution Company Website https://corex.solutions/

August 26, 2024 06:51 AM Eastern Daylight Time

Hove Capital Management Explores Potential Strategic Partnerships with BNP Paribas and Société Générale”

Pinion Newswire

Hove Capital Management, a leading force in the fixed rate bond market with over 20 years of industry expertise, is seeking new strategic alliances with two of Europe’s foremost financial institutions: BNP Paribas and Société Générale. These collaborations will mark a significant milestone in Hove Capital Management’s mission to enhance its service offerings and extend its global presence. These potential partnerships underscore Hove Capital Management’s commitment to leveraging collective strengths to drive innovation, improve client services, and deliver superior financial products tailored to the evolving market landscape. “We are pleased to announce that, after much deliberation, The Banque de France has granted its approval, allowing these partnerships to proceed,” said Richard O’Brien, Senior Partner at Hove Capital Management. “This approval is a crucial step, and its receipt has paved the way for our collaborations with BNP Paribas and Société Générale to move forward. We are excited about the new opportunities this approval unlocks and its positive impact on our ability to serve our clients more effectively.” The collaboration with BNP Paribas and Société Générale will enable Hove Capital Management to deepen its market engagement and reinforce its presence across pivotal financial hubs in Europe. This potential expansion aims to harness local expertise and insights crucial for navigating regional market complexities. The partnerships will also enhance Hove Capital Management’s analytical capabilities and provide a broader perspective on global economic trends. “Entering into these collaborations allows us to share knowledge, risk management strategies, and resources, positioning us to meet our clients’ financial goals better,” added Richard O’Brien. “We are particularly excited about the potential these partnerships have to advance our analytical capabilities and broaden our understanding of global economic trends.” Hove Capital Management has meticulously planned these collaborations to align with its core values and long-term objectives. The company remains focused on its mission to deliver high-quality, customized bond brokerage services by continuously adapting to market needs and enhancing operational efficiency. Hove Capital Management anticipates that these strategic partnerships will not only strengthen its market position but also foster innovation within the fixed-rate bond sector. For the latest updates and more information about Hove Capital Management and its services, please visit hovecapitalmanagement.com Contact Details Hove Capital Management Peter Nobel +1 917-601-3863 p.nobel@hovecapitalmanagement.com Company Website https://hovecapitalmanagement.com/

August 23, 2024 01:16 PM Eastern Daylight Time

RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Benzinga

By Meg Flippin, Benzinga A potential, previously unexplored pathway for fighting diabetes and obesity-related disorders may have been unveiled by RedHill Biopharma (NASDAQ: RDHL), a specialty biopharmaceutical company, and its partner Apogee Biotechnology Corp., who are busy developing what may be an interesting new approach in the obesity and diabetes market. The company is testing opaganib in a range of metabolic disease models designed to show its potential to prevent and treat type 2 diabetes and other obesity-related diseases and recently received positive in vivo results. The positive results of early trials are good news for RedHill Biopharma given the global obesity-diabetes drug market opportunity is huge, projected to reach $100 billion by 2030. It’s being driven largely by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk’s (NYSE: NVO) Ozempic and Wegovy (semaglutide), Eli Lilly’s (NYSE: LLY) Trulicity (dulaglutide) and Mounjaro (tirzepatide) and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim’s Jardiance (Empagliflozin), reports RedHill. If RedHill is right about opaganib, it could join those ranks. “Sphingolipid metabolism is implicated in insulin resistance, β-cell disruption, adipocyte function, inflammation and immune regulation, vascular complications and energy metabolism – all significant components of obesity, diabetes and their associated complications,” said Charles D. Smith, Ph.D. Founder and CEO of Apogee Biotechnology Corp., Redhill’s partner who led the testing of opaganib for the treatment and prevention of type 2 diabetes and other obesity-related disorders. “Opaganib’s ability to modulate multiple signaling pathways through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells provides a strong rationale for evaluation of opaganib in obesity-related disorders.” Opaganib Slows Weight Gain Earlier this week RedHill announced that in vivo studies conducted by RedHill’s partner, Apogee, yielded positive results. The studies looked at the impact opaganib had on weight gain and glucose tolerance in a high-fat diet (HFD) model. They demonstrated opaganib suppressed HFD-induced body weight gain, loss of glucose tolerance and fat deposition. Additionally, opaganib reduced weight gain and restored glucose tolerance in an already obese HFD model, suggesting its potential for treating, not just preventing, obesity-related disorders, reports RedHill Biopharma. “Sphingolipid metabolism is a key pathway in many diseases, including obesity, but has not been adequately examined as a therapeutic target for human therapy,” said Dr. Mark Levitt, Chief Scientific Officer at RedHill. “Opaganib, which acts as a sphingosine competitor, is the first clinical drug to target three key enzymes in this pathway.” With multiple U.S. government collaborations ongoing, opaganib, RedHill Biopharma’s first-in-class new chemical entity with anti-inflammatory, anti-cancer and antiviral activity, is a host-directed, potentially broad-acting, orally administered small molecule drug with demonstrated safety & efficacy profiles. It is in development for multiple oncology, viral, inflammatory and diabetes and obesity-related indications, including COVID-19, Ebola, acute respiratory distress syndrome (ARDS) and radio/chemical protection. More Than Fighting Diabetes But it’s not just in fighting diabetes and obesity-related disorders where RedHill is making progress. Adding to its commercialization by RedHill in the U.S., the company just launched Talicia (omeprazole magnesium, amoxicillin and rifabutin) in the United Arab Emirates (UAE) – making it available by prescription to treat adults with Helicobacter pylori ( H. pylori ) infection. Talicia is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori. The commercial launch of Talicia in the UAE triggers RedHill’s eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole). In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults. In a pivotal Phase 3 study, Talicia demonstrated 84% eradication of H. pylori infection in the intent-to-treat (ITT) group vs. 58% in the active comparator arm (p<0.0001). “As one of the strongest risk factors for gastric cancer, H. pylori is a major public health concern,” said Rick Scruggs, President & Chief Commercial Officer at RedHill. “With 41% of the UAE population infected by H. pylori and the alarming failure rates of clarithromycin-based therapies, there is a significant medical need for a highly effective first-line H. pylori therapy. Our efforts to make Talicia available to patients in more countries continue as we work to explore additional opportunities with existing and potential partners.” From preventing diabetes and obesity-related diseases to fighting H. pylori, RedHill Biopharma seems to be making strides with its key drug compounds. Early testing shows promise, potentially making this a company worth watching. To learn more about RedHill Biopharma’s pipeline, click here. Featured photo by Diana Polekhina on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 23, 2024 08:30 AM Eastern Daylight Time

Image

1 ... 77 78 79 80 81 ... 3773